Vericel Corp (NASDAQ:VCEL) – Analysts at Oppenheimer boosted their Q4 2019 EPS estimates for shares of Vericel in a research report issued on Tuesday, October 8th. Oppenheimer analyst K. Degeeter now expects that the biotechnology company will post earnings of $0.20 per share for the quarter, up from their prior forecast of $0.19. Oppenheimer also issued estimates for Vericel’s FY2020 earnings at $0.40 EPS, FY2021 earnings at $0.77 EPS, FY2022 earnings at $1.58 EPS and FY2023 earnings at $1.91 EPS.
Vericel (NASDAQ:VCEL) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.42. Vericel had a negative return on equity of 0.99% and a negative net margin of 18.14%. The firm had revenue of $26.15 million for the quarter, compared to analyst estimates of $24.13 million. During the same period last year, the company earned ($0.12) earnings per share. The firm’s revenue for the quarter was up 37.6% on a year-over-year basis.
VCEL has been the topic of several other reports. Zacks Investment Research raised Vericel from a “hold” rating to a “buy” rating and set a $17.00 target price on the stock in a research report on Saturday, October 5th. ValuEngine lowered Vericel from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. BidaskClub lowered Vericel from a “hold” rating to a “sell” rating in a research report on Friday, September 6th. BTIG Research set a $24.00 target price on Vericel and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, HC Wainwright started coverage on Vericel in a research report on Wednesday. They issued a “buy” rating and a $19.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $21.98.
Shares of NASDAQ VCEL opened at $14.45 on Thursday. Vericel has a 1-year low of $10.51 and a 1-year high of $21.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.50 and a quick ratio of 7.12. The business’s fifty day moving average price is $15.67 and its two-hundred day moving average price is $17.12. The firm has a market capitalization of $643.12 million, a PE ratio of -103.21 and a beta of 2.66.
In other news, CEO Dominick Colangelo sold 58,125 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $14.88, for a total transaction of $864,900.00. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Gerard J. Michel sold 17,000 shares of the firm’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $19.68, for a total value of $334,560.00. The disclosure for this sale can be found here. Insiders have sold 92,125 shares of company stock worth $1,482,000 over the last three months. Corporate insiders own 4.50% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Advisory Services Network LLC increased its holdings in shares of Vericel by 1,400.0% during the first quarter. Advisory Services Network LLC now owns 1,500 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 1,400 shares during the period. Royal Bank of Canada boosted its stake in Vericel by 665.8% during the second quarter. Royal Bank of Canada now owns 1,547 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,345 shares in the last quarter. Advisor Group Inc. boosted its stake in Vericel by 152.1% during the second quarter. Advisor Group Inc. now owns 2,652 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 1,600 shares in the last quarter. Aperio Group LLC bought a new position in Vericel during the second quarter valued at about $67,000. Finally, SG Americas Securities LLC bought a new position in Vericel during the first quarter valued at about $109,000. 88.74% of the stock is currently owned by institutional investors.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Recommended Story: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.